Antoine Cherfan, Pharm.D., BCPS, FCCP, CACP .Manager of Pharmacotherapy Services .Department of Pharmacy Services. Cleveland clinic Abudhabi. UAE
Cleveland Clinic Abu Dhabi (CCAD) opened its doors in March 2015 providing inpatient and outpatient services through 5 major institutes of practice through a state of art facility with the highest level of automation.
Establishing a unique and advanced practice pharmacotherapy services at CCAD was a requirement, a vision and a challenge. We had to consider the scope of services and identify the necessary infrastructure to operate including the necessary manpower and needed expertise; add to that identify challenges and pertinent solutions.
Establishing a therapeutic drug formulary and putting it into effective use was one of our early tasks as the cornerstone for the pharmacotherapy practice of any medical center. As such, the pharmacotherapy services had the privilege to establish the formulary at CCAD. Putting the formulary into effective use through build of drug records, ordersets and protocols was our next lightening success where we worked to optimize the use of the provided technology with pertaining complexity to implement best practices and ensure safe and effective drug therapy. We managed to apply pharmacotherapy through technology; a comprehensive system based approach.
In addition to the contributions at the system level, we laid the infrastructure for direct patient care. We established our own managed inpatient pharmacotherapy consult services and anticoagulation and heart failure clinics with policies and procedures, workflows and electronic medical records functionalities required to facilitate our services and allow us to measure key performance indicators. Additional outpatient services need to develop and evolve to ensure more involvement in the patient therapy across the continuum of care.
The future pharmacotherapy services need to align with the patient needs and emerging trends of therapy. Pharmacists are uniquely positioned to lead the implementation of pharmacogenomics and providing opportunities to proactively improve medication use and safety. We need also to evaluate the implications of new specialty medications, especially for rare diseases and chronic conditions and expand the health system’s capacity to manage all specialty medications to promote safe use, optimize outcomes, and foster wise use of resources.